[Congressional Bills  113th Congress] [From the U.S. Government Printing Office] [S. 2813 Introduced in Senate (IS)] 113th CONGRESS   2d Session                                 S. 2813     To establish the National Prostate Cancer Council for improved    screening, early detection, assessment, and monitoring of prostate  cancer, and to direct the development and implementation of a national    strategic plan to expedite advancement of diagnostic tools and the                    transfer of such tools to patients. _______________________________________________________________________                    IN THE SENATE OF THE UNITED STATES                            September 16, 2014   Mrs. Boxer (for herself and Mr. Sessions) introduced the following    bill; which was read twice and referred to the Committee on Health,                       Education, Labor, and Pensions _______________________________________________________________________                                  A BILL       To establish the National Prostate Cancer Council for improved    screening, early detection, assessment, and monitoring of prostate  cancer, and to direct the development and implementation of a national    strategic plan to expedite advancement of diagnostic tools and the                    transfer of such tools to patients.     Be it enacted by the Senate and House of Representatives of the  United States of America in Congress assembled, SECTION 1. SHORT TITLE.     This Act may be cited as the ``National Prostate Cancer Council  Act. SEC. 2. NATIONAL PROSTATE CANCER COUNCIL.     (a) Establishment.--There is established in the Office of the  Secretary of Health and Human Services (referred to in this section as  the ``Secretary) the National Prostate Cancer Council on Screening,  Early Detection, Assessment, and Monitoring of Prostate Cancer  (referred to in this Act as the ``Council).     (b) Purpose of the Council.--The Council shall--             (1) develop and implement a national strategic plan for the          accelerated creation, advancement, and testing of diagnostic          tools to improve screening, early detection, assessment, and          monitoring of prostate cancer, including--                     (A) early detection of aggressive prostate cancer                  to save lives;                     (B) monitoring of tumor response to treatment,                  including recurrence and progression; and                     (C) accurate assessment and surveillance of                  indolent disease to reduce unnecessary biopsies and                  treatment;             (2) provide information and coordination of prostate cancer          research and services across all Federal agencies;             (3) review diagnostic tools and their overall effectiveness          at screening, detecting, assessing, and monitoring of prostate          cancer;             (4) evaluate all programs in prostate cancer that are in          existence on the date of enactment of this Act, including          Federal budget requests and approvals and public-private          partnerships;             (5) submit an annual report to the Secretary and Congress          on the creation and implementation of the national strategic          plan under paragraph (1); and             (6) ensure the inclusion of men at high-risk for prostate          cancer, including men from ethnic and racial populations and          men who are least likely to receive care, in clinical,          research, and service efforts, with the purpose of decreasing          health disparities.     (c) Membership.--             (1) Federal members.--The Council shall be led by the          Secretary or designee and comprised of the following experts:                     (A) Two representatives of the National Institutes                  of Health, including 1 representative of the National                  Institute of Biomedical Imaging and Bioengineering and                  1 representative of the National Cancer Institute.                     (B) A representative of the Centers for Disease                  Control and Prevention.                     (C) A representative of the Centers for Medicare                  and Medicaid Services.                     (D) A designee of the Director of the Department of                  Defense Congressionally Directed Medical Research                  Program.                     (E) A designee of the Director of the Office of                  Minority Health.                     (F) A representative of the Food and Drug                  Administration.                     (G) A representative of the Agency for Healthcare                  Research and Quality.             (2) Non-federal members.--In addition to the members          described in paragraph (1), the Council shall include 16 expert          members from outside the Federal Government, which shall          include at least--                     (A) 6 prostate cancer patient advocates,                  including--                             (i) 2 patient-survivors;                             (ii) 2 caregivers of prostate cancer                          patients; and                             (iii) 2 representatives from national                          prostate cancer disease organizations that fund                          research or have demonstrated experience in                          providing assistance to patients, families, and                          medical professionals, including information on                          health care options, education, and referral;                          and                     (B) 8 health care stakeholders with specific                  expertise in prostate cancer research in the critical                  areas of clinical expertise, including medical                  oncology, radiology, radiation oncology, urology, and                  pathology.     (d) Meetings.--The Council shall meet quarterly and meetings shall  be open to the public.     (e) Advice.--The Council shall advise the Secretary, or the  Secretarys designee.    (f) Annual Report.--The Council shall submit annual reports, beginning not later than 1 year after the date of enactment of this Act, to the Secretary or the Secretarys designee and to Congress. The  annual report shall include--             (1) in the first year--                     (A) an evaluation of all federally funded efforts                  in prostate cancer research and gaps relating to the                  development and validation of diagnostic tools for                  prostate cancer; and                     (B) recommendations for priority actions to expand,                  eliminate, coordinate, or condense programs based on                  the performance, mission, and purpose of the programs;                  and             (2) annually thereafter for 5 years--                     (A) an outline for the development and                  implementation of a national research plan for creation                  and validation of accurate diagnostic tools to improve                  prostate cancer care in accordance with subsection (a);                     (B) roles for the National Cancer Institute,                  National Institute on Minority Health and Health                  Disparities, and the Office on Minority Health of the                  Department of Health and Human Services;                     (C) an analysis of the disparities in the incidence                  and mortality rates of prostate cancer in men at high                  risk of the disease, including individuals with family                  history, increasing age, or African-American heritage;                  and                     (D) a review of the progress towards the                  realization of the proposed strategic plan.     (g) Termination.--The Council shall terminate on December 31, 2019.     (h) Authorization of Appropriations.--There are authorized to be  appropriated to carry out this section $2,000,000 for the period of  fiscal years 2015 through 2019.                                  &lt;all&gt; 
